A retrospective cohort study from 2017 by Snast I et al. showed that the yearly reactivation rates were higher in those patients with a chronic hepatitis B virus infection (13.92%) on TNF-alpha inhibitors than for patients with resolved infection (0.32%) [69]. The gene discussed is TNF; the disease is chronic hepatitis B virus infection.